Published in final edited form as:

Invest New Drugs. 2013 February ; 31(1): 213–229. doi:10.1007/s10637-012-9837-3.

Investigational Agents in Development for the Treatment of Ovarian Cancer

Shannon N. Westin, MD, MPH¹, Thomas J. Herzog, MD², and Robert L. Coleman, MD¹

¹Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

²Division of Gynecologic Oncology, Department of OB/GYN, Columbia University College of Physicians and Surgeons, New York, NY

Abstract

Although significant success has been achieved in the treatment of advanced and recurrent ovarian cancer, there is clearly room for improvement. The use of targeted agents in this patient population has the promise to provide improved survival and quality of life. There are a myriad of relevant pathways under exploration in all settings of ovarian cancer. Clinical trial data are accumulating for antiangiogenic therapy, including vascular endothelial growth factor (VEGF)-specific inhibitors and multiple angiogenic signaling target inhibitors, as well as poly-ADP-ribose polymerase (PARP) inhibitors. Other types of tumorigenic pathway inhibitors, including those that target phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR), protein kinase B (AKT), Src, folate receptor alpha, and insulin-like growth factor-1 receptor (IGF-1R) pathways are in earlier phases of development for ovarian cancer. Attempts to target the epidermal growth factor receptor (EGFR) of ovarian tumors have been met with limited success; however, newer agents that inhibit this pathway show promise. Finally, with recognition of the role of Wee-1 in p53-deficient tumors, an inhibitor of this tyrosine kinase is being evaluated in recurrent ovarian cancer. The logistical challenge is to determine the optimal timing and proper combinations of novel agents independently as well as concomitantly with conventional chemotherapeutics. Reported results have been modest; however, our growing understanding of these pathways will be potentially reflected in greater impact on response and survival.

Keywords

ovarian cancer; targeted therapy; personalized therapy; resistance; angiogenesis

Corresponding Author: Shannon N. Westin, MD, MPH, University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Blvd, Unit 1362, Houston, TX 77030, swestin@mdanderson.org, Telephone: 713-794-4314, Fax: 713-792-7586.

Conflict of Interest: Dr. Westin serves on the scientific advisory board for OCT, Inc. Dr. Herzog has served on advisory boards for Morphotek, Inc, Nektar Therapeutics, Roche, Endocyte, and Johnson & Johnson. Dr. Coleman serves on the scientific steering committees and/or receives research funding from Morphotek, Inc, Nektar Therapeutics, Roche/Genentech, Johnson & Johnson, AstraZeneca, sanofi-aventis, Novartis, Esperance Pharmaceuticals, Inc, Boehringer Ingelheim, Vermillion, Inc, Endocyte, Inc, and GlaxoSmithKline.

Introduction

Ovarian cancer is the second most common gynecologic cancer and the most frequent cause of gynecologic cancer-related death in the United States. Current estimates for 2012 suggest that 22,280 women will be diagnosed with ovarian cancer and 15,500 will die of their disease [1]. It is encouraging that the incidence of ovarian cancer has remained stable since 1992 and death rates decreased by 1.9% per year from 2004 to 2008. However, the majority of patients (63%) are still diagnosed with distant disease and 5-year survival rates only reach 27% [1]. These dismal rates occur despite the high chemosensitivity of ovarian cancer, where 50-80% of patients will achieve a response or lack of progression of disease after treatment with primary therapy [2-5], which generally includes a combination of surgical cytoreduction and platinum and taxane-based chemotherapy [6]. High rates of relapse in the first 2 years following therapy and the emergence of drug resistance highlight the key barriers to improving clinical outcomes [2].

Interestingly, there is currently no therapeutic agent recommended as the treatment of choice for platinum-resistant recurrent ovarian cancer [6]. This underscores the critical need to develop novel agents and combinations in this population to impact overall survival (OS) while preserving quality of life. The use of targeted agents which act on pathways involved in tumorigenesis promises to reduce mortality from ovarian cancer while reducing morbidity associated with treatment by focusing on abnormal rather than normal tissues. The majority of current research in advanced and recurrent ovarian cancer focuses on the inhibition of signal transduction pathways and targeting DNA repair mechanisms. This review will discuss investigational agents in development for the treatment of ovarian cancer, including therapies targeted at single (with tyrosine kinase inhibitors [TKIs] or monoclonal antibodies) or multiple (with TKIs) signaling pathways in angiogenesis, cellular survival, and DNA repair (Table 1). Special attention will be paid to the development of resistance to these therapies, and the need for rational combinations to avoid further disappointments in the treatment of ovarian cancer.

Targeting Angiogenesis

Arguably, the greatest success in targeted therapy for ovarian cancer to date has been among agents that target angiogenesis (Figure 1). Angiogenesis is critical for normal ovarian physiology and plays a fundamental role in the pathogenesis of ovarian cancer by promoting tumor growth, progression, and metastatic spread [7, 8]. Vascular endothelial growth factor (VEGF) and its receptor, VEGFR, are expressed in many tumor types, including ovarian cancer [8, 9]. High levels of expression of VEGFR in ovarian cancer have been associated with increased tumor growth, metastases, and higher mortality rates [10, 11]. Furthermore, increased VEGF expression has been found in malignant ascites and is associated with its development [8, 12].

VEGF-specific inhibitors in ovarian cancer

Bevacizumab (Avastin[®], Genentech; South San Francisco, CA, USA), a humanized monoclonal antibody to human VEGF, is the most widely studied targeted agent in ovarian cancer. Unlike in other tumor types [13], bevacizumab has demonstrated single-agent

activity in ovarian cancer, likely explained by the dual antitumor and antiangiogenic activity induced by VEGF inhibition [14]. Two phase II trials of bevacizumab as a single agent in heavily pretreated patients with relapsed ovarian cancer yielded response rates (RRs) of 16% and 21%, with a median progression-free survival (PFS) of 4.4 and 4.7 months, respectively [15, 16]. In the study by Burger and colleagues, 40.3% of patients had a PFS of at least 6 months, with patients receiving a median number of 7 cycles (1 or 2 prior regimens required) [16]. However, activity of bevacizumab in these trials was offset by higher toxicity, with 4 of 44 (11%) patients in the Cannistra study having gastrointestinal perforation (GIP), leading to early termination for toxicity concerns. The risk of perforation was higher in those patients with more prior chemotherapy treatments and in whom impending bowel obstruction was suspected; however, a clear risk-based model has yet to be elucidated and may vary by clinical setting where the agent is studied [15]. Further studies are ongoing to define a clear set of risk factors for perforation in the setting of bevacizumab therapy.

The combination of bevacizumab with cytotoxic agents has great promise in recurrent ovarian cancer. Bevacizumab was combined with metronomic oral cyclophosphamide in a cohort of patients with multiple prior lines of chemotherapy. With minimal toxicity, this study achieved a RR of 24% at a median follow up of 23.2 months. Further, PFS at 6 months was 56% [17]. A single-arm trial of bevacizumab with carboplatin and pegylated liposomal doxorubicin (PLD) in platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer yielded an objective RR of 72.2% among 54 patients. PFS was 14.1 months and median response duration was 12.1 months, with 13 patients experiencing drug-related serious adverse events (gastrointestinal, infectious, procedural, respiratory, and/or vascular) [18]. The OCEANS trial combined bevacizumab with at least 6 cycles (up to 10 cycles allowed) of standard carboplatin and gemcitabine followed by bevacizumab (or placebo) maintenance in the treatment of platinum-sensitive recurrent ovarian cancer. The bevacizumab arm demonstrated a 4-month improvement in PFS compared with placebo (hazard ratio [HR], 0.484; 95% confidence interval [CI], 0.388-0.605; $P < 0.0001$); OS data are not mature [19]. Gynecologic Oncology Group (GOG) 213 is an ongoing bifactorial randomized study to evaluate the impact of bevacizumab in addition to paclitaxel and carboplatin on OS in platinum-sensitive patients (NCT00565851). Additionally, the study examines the role of secondary surgical cytoreduction in this patient population.

In the platinum-resistant setting, the fully accrued AURELIA trial is comparing bevacizumab in combination with standard recurrent disease chemotherapy agents, including paclitaxel, PLD, or topotecan, to the standard agent alone (NCT00976911). Other studies have combined bevacizumab with cyclophosphamide [17, 20], topotecan [21], PLD [22], nab-paclitaxel [23], and docetaxel (Table 2) [24].

Bevacizumab has also been combined with other biologics in recurrent Müllerian cancers. A phase II trial combined with erlotinib, a TKI to epidermal growth factor receptor (EGFR), demonstrated a RR of 15% and 54% had stable disease (SD). However, there was no clear benefit over single-agent bevacizumab and the rate of GIP was quite high (15%) [25].

Given the activity of bevacizumab in combination with paclitaxel and carboplatin in early phase trials in the front-line setting [26, 27], 2 large phase III trials have been recently completed in previously untreated advanced ovarian cancer (Table 2) [28, 29]. In the GOG 218 study, patients who received bevacizumab and cytotoxic chemotherapy followed by maintenance bevacizumab had significantly improved PFS versus those who received chemotherapy alone (median 14.1 vs. 10.3 months; HR, 0.717; 95% CI, 0.625-0.824; $P < 0.001$). Of note, there was no significant difference in PFS between patients who received bevacizumab and chemotherapy without maintenance bevacizumab compared with those who received chemotherapy alone (median 11.2 vs. 10.3 months; HR, 0.908; 95% CI, 0.795-1.040; $P = 0.16$) suggesting duration of exposure may be important to the treatment strategy [28].

Although the design is somewhat different, primary results from the International Collaborative Ovarian Neoplasm (ICON) 7 trial support a PFS benefit among patients in the arm treated with bevacizumab in addition to standard chemotherapy followed by maintenance bevacizumab after a 19.4-month median follow-up (19.0 vs. 17.3 months; HR, 0.81; 95% CI, 0.70-0.94; $P = 0.004$) [30], with similar findings after an updated analysis (after a 28-month median follow-up) [29]. Survival data are not yet mature for either trial; however, preliminary results reveal no OS benefit for bevacizumab plus chemotherapy followed by maintenance bevacizumab versus the control arm (HR, 0.0915 [95% CI, 0.727-1.152; $P = 0.45$] and 0.84 [95% CI, 0.69-1.04; $P = 0.11$] for GOG 218 and ICON7, respectively) [28, 29]. Adverse events associated with bevacizumab in GOG 218 and ICON7 were similar. The frequency of most adverse events was comparable between the bevacizumab and control arms aside from increased incidence of hypertension among bevacizumab recipients in both studies [28, 29]. Additional studies are ongoing to explore bevacizumab in combination with chemotherapy to determine its optimal role in ovarian cancer therapy (NCT00951496 [GOG 252], NCT01167712 [GOG 262], NCT01081262, NCT00483782).

Aflibercept (VEGF Trap, Regeneron; Tarrytown, NY, USA) is a manufactured protein engineered through fusion of the ligand-binding domains of human VEGFR-1 and VEGFR-2 with the constant region of IgG. This agent binds all isoforms of VEGF as well as placental growth factor [31]. Two phase II studies of aflibercept as a single agent in platinum-resistant ovarian cancer have demonstrated promising results given a heavily pretreated population [32, 33]. In a study of 162 patients, the RR was 11% with 5 partial responses (PRs) and no mention of SD [33]. As a treatment for malignant ascites, Gotlieb and colleagues found that the mean time to repeat paracentesis was prolonged with aflibercept ($P = 0.019$) compared with placebo; however, the incidence of fatal gastrointestinal events was higher with aflibercept (3 intestinal perforations) versus placebo (1 intestinal fistula leading to sepsis) [32]. Due to promising results in phase I trials, Coleman and colleagues recently reported the results of a phase II trial of aflibercept in combination with docetaxel in recurrent ovarian cancer. Overall the confirmed RR was 54% (11 CRs and 14 PRs among 46 evaluable patients), with impressive response in platinum-sensitive (77% [10 of 13]) and platinum-resistant (45% [15 of 33]) patients. Median duration of response was 6.0 months and median PFS and OS in the entire group were 6.4 months

and 26.6 months, respectively. Adverse events were mostly of grade 1/2 severity; the most common grade 3/4 events (5% of patients) were fatigue, dyspnea, neutropenia, leukopenia, and stomatitis [34].

Although RRs have been quite impressive with the use of anti-VEGF therapies, there are patients that do not respond to initial treatment and also those that develop resistance to these therapies. There are multiple excellent reviews on the topic of antiangiogenic therapy resistance as a thorough discussion is beyond the scope of this article [35-37]. Briefly, it appears there are multiple mechanisms at work, including development of tumor hypoxia that may lead to more aggressive behavior and sustained survival. In addition, it appears that other angiogenic pathways are stimulated when VEGF blockade is achieved, leading to compensatory activation of angiogenesis. Finally, the tumor microenvironment, including fibroblasts and pericytes, protect tumor cells from the action of agents targeting VEGF. Targeting other angiogenic signaling pathways is one option to overcome the development of resistance to these therapies.

Other angiogenic targets of importance

Although VEGF and related receptors have been the primary focus for clinical targets heretofore, the development of resistance and the failure to achieve CR have led to great interest in other members in the antiangiogenic cascade. Several other targets have gained focus in light of their apparent importance in ovarian cancer and the potential for successful inhibition. For example, higher levels of platelet-derived growth factor (PDGF) have been found in ovarian carcinomas than in benign tissue and in malignant ascites, and have been associated with poor survival [38-44]. In addition, the fibroblast growth factor (FGF) pathway has also been implicated in angiogenesis and ovarian physiology [45-50] and ascites [48]. Furthermore, both PDGF [41, 51, 52] and FGF signaling [36, 53, 54] have been implicated in resistance to VEGF inhibition, suggesting that combined inhibition of VEGF and PDGF and/or FGF would more effectively block angiogenesis than isolated VEGF inhibition [52, 55-57].

The inhibition of multiple angiogenic signaling targets is characteristic of several drugs currently under development, some with potentially promising early results. Cediranib (Recentin™, AstraZeneca; Wilmington, DE, USA) demonstrates strong inhibition of VEGFR-1, -2, -3 and c-kit, in addition to lower affinity inhibition of PDGFR- α/β , and fibroblast growth factor receptor 1 (FGFR-1) [58]. In a study of this agent in 46 patients with recurrent ovarian cancer, a clinical benefit rate of 30% was achieved with acceptable toxicity. Successful outcomes included 8 patients with PR, 6 patients with SD, and a median PFS of 5.2 months [59]. Hirte and colleagues reported a 41% RR in platinum-sensitive patients and a 29% RR in patients with platinum-resistant ovarian cancer treated with cediranib. The median time to progression and OS in the cohort were 4.1 and 11.9 months, respectively [60]. A phase II/III trial is evaluating cediranib in combination with paclitaxel and carboplatin and as maintenance therapy in platinum-sensitive recurrent ovarian cancer (NCT00544973 [ICON6]). Blinded safety results for 60 patients treated in stage I (for which safety was the primary outcome) have been published, supporting trial expansion to stage II [61].

Nintedanib (BIBF 1120, Boehringer Ingelheim; Ingelheim, Germany) is a triple angiokinase inhibitor that targets several key angiogenic receptors including VEGFR-1, -2, and -3, PDGFR- α/β , and FGFR-1, -2, and -3. In addition, this agent has activity against members of the v-src sarcoma viral oncogene homolog (Src) family and fms-like tyrosine kinase 3 (Flt-3) [62]. A phase I study of nintedanib combined with paclitaxel and carboplatin in patients with advanced or recurrent gynecologic malignancies had promising results with 5 of 7 patients with measurable disease demonstrating response and 2 achieving SD. Of the patients with response, 3 had recurrent ovarian cancer. Overall, the treatment was well tolerated with primarily gastrointestinal adverse events that were grade 1 to 2 in severity [63]. Nintedanib has also been assessed as a maintenance therapy among patients with recurrent ovarian cancer who responded to their last chemotherapy regimen, defined as CR, PR, or 50% reduction in CA125. Treatment with nintedanib yielded a 36-week PFS rate of 16.3% compared with 5.0% in patients treated with placebo (HR, 0.65; 95% CI, 0.42-1.02; $P = 0.06$). Patients receiving nintedanib maintenance experienced significantly more nausea, vomiting, and diarrhea (mostly of grade 1/2 severity) compared with those treated with placebo [64]. Grade 3/4 adverse events were similar between groups, with the exception of grade 3 liver enzyme elevations (51.2% with nintedanib vs. 7.5% with placebo). These results led to the development of a randomized phase III study of nintedanib in combination with paclitaxel and carboplatin in the upfront setting for advanced ovarian cancer followed by nintedanib monotherapy as maintenance (NCT01015118 [AGO-OVAR12/LUME-Ovar1]). Treatment with nintedanib is to be continued until toxicity, disease progression, or a maximum of 120 weeks is reached. Two ongoing phase I studies are investigating the combination of nintedanib with carboplatin and PLD in platinum-sensitive relapsed ovarian cancer (NCT01329549; NCT01314105).

Pazopanib (GlaxoSmithKline; London, UK) is an agent that inhibits signaling through VEGFR-1, -2, and -3, PDGFR- α/β , FGFR-1 and -3, and c-kit [65, 66]. This small molecule inhibitor has been evaluated in a phase II study of 31 patients with recurrent ovarian cancer with elevated CA125 and non-bulky disease. This study reported a 31% RR by CA125 level and a 56% SD rate. Among 17 patients with measurable disease, 18% achieved a PR [67]. Phase II studies in relapsed/resistant ovarian cancer of pazopanib as a single agent (NCT01262014, NCT01227928) and in combination with chemotherapy (NCT01238770, NCT01035658) are ongoing. In addition, a phase III study evaluating single-agent pazopanib maintenance after first-line chemotherapy has recently completed enrollment (NCT00866697).

Sorafenib (Nexavar[®], Bayer; Leverkusen, Germany) is an interesting small molecule inhibitor that effectively inhibits several angiogenesis-related receptors (VEGFR-2 and -3, PDGFR- β , c-kit, Flt-3) as well as Raf [68]. Matei and colleagues reported a phase II trial of this agent in recurrent ovarian cancer after 1 or 2 prior therapies. Twenty-two of 59 patients achieved PR or SD with common toxicities of gastrointestinal, constitutional, and dermatologic events. Fourteen patients with measurable disease were progression free for 6 months or greater [69]. A phase I study of the combination of sorafenib with bevacizumab had an impressive RR of 46% in heavily pretreated ovarian cancer. Toxicity was common in this study, including diarrhea, fatigue, hypertension, hand-foot syndrome, and transaminitis,

leading to dose-reduction in the majority (74%) of patients [70]. A subsequent phase II study of intermittently dosed sorafenib with bevacizumab yielded clinical benefit in 88% of the first 25 response-evaluable patients (including 6 PRs and 16 patients with SD) with recurrent ovarian cancer. The most common grade 3/4 adverse events included hypertension and thrombosis [71]. Phase II studies combining sorafenib with traditional second-line chemotherapy, including topotecan [72] and gemcitabine [73], have yielded similar clinical benefit rates with minimal additional toxicity. Sorafenib is under evaluation in several phase II trials in combination with chemotherapy (NCT00096200, NCT01047891) in recurrent ovarian cancer, in the first-line setting in combination with standard chemotherapy (NCT00390611), and as a maintenance therapy after complete clinical response (NCT00791778).

Sunitinib (Sutent[®], Pfizer; New London, CT, USA) inhibits VEGFR-2, PDGFR- β , c-kit, Flt-3, and the rearranged during transfection (RET) proto-oncogene [74-78]. Single-agent sunitinib has been evaluated in 3 phase II studies in patients with recurrent or refractory ovarian cancer [79-81]. RRs among the 3 trials ranged between 3.3% to 19% [79-81] and SD rates were between 19% and 53% [79-81]. Common side effects were hand-foot reaction, gastrointestinal symptoms, fatigue, hypertension, and mucositis [80]. The utility of this agent in all types of ovarian cancer is unclear; however, sunitinib is under exploration for the treatment of advanced and recurrent ovarian cancer of clear cell histology (NCT00979992 [GOG 254]).

Cabozantinib (XL-184, Exelixis, Inc; South San Francisco, CA, USA) is new chemical entity that targets multiple receptor tyrosine kinases promoting angiogenic, invasive and metastatic properties, including RET, mesenchymal-epithelial transition (MET), VEGFR-2, and c-kit. It has demonstrated preclinical and clinical activity across a number of solid tumors, including ovarian, medullary thyroid, and castrate-resistant prostate cancer. A recent phase II randomized discontinuation trial of cabozantinib in recurrent, previously treated ovarian cancer was stopped early based on an encouraging 12-week RR of 24% in a mixed population (18% in platinum-resistant, 29% in platinum-sensitive patients) [82]. The median duration of response and PFS had not been reached after a median follow-up of 4 months. Grade 3 adverse events were hand-foot syndrome and diarrhea. A placebo-controlled phase II trial of cabozantinib for progressive recurrent or advanced solid tumors (including ovarian) is ongoing (NCT00940225).

Targeting DNA Repair With Poly-ADP-Ribose Polymerase (PARP) Inhibition

Increased signaling through DNA damage repair pathways is a known mechanism of chemoresistance. PARP1 is an enzyme that plays a critical role in the repair of DNA single-strand breaks through base-excision repair [83]. Loss of PARP1 activity leads to accumulation of single-strand breaks, subsequent double-stranded breaks, and cellular death. In normal cells, double-stranded breaks are repaired through homologous recombination [84].

Defects in DNA repair occur in carriers of *breast cancer susceptibility gene 1 (BRCA1)* and *BRCA2* gene mutations, whether germline or somatic, as well as in patients with defects in

the homologous recombination pathway [85, 86]. The use of PARP inhibitors in patients with defects in DNA repair is a rational approach, as PARP inhibition in these tumor cells leads to double-stranded DNA accumulation and cell death via a process known as synthetic lethality. Germline *BRCA1* and *BRCA2* mutations occur in approximately 5% to 10% of patients with ovarian cancer [87-89]. In addition, recent findings indicate that somatic mutations in *BRCA1* and *BRCA2* are also common, suggesting that additional patients may be sensitive to PARP inhibition [90]. Furthermore, the hypermethylation of DNA leading to loss of function of the *BRCA1* gene has also been observed in up to 31% of sporadic ovarian cancers [91]. Certain histology types, such as high grade serous adenocarcinoma, may respond to PARP inhibitors in the absence of *BRCA* mutation. Recent studies have attempted to identify patients with a “BRCAness” phenotype to determine those that might benefit most from treatment with these agents [90, 92].

While several PARP inhibitors are currently being investigated (Table 3), the most experience to date in ovarian cancer is with olaparib (AZD2281, AstraZeneca; Wilmington, DE, USA) in patients with *BRCA1* and *BRCA2* mutations. In an ongoing phase II trial evaluating 2 doses of olaparib in 57 patients with *BRCA1* and *BRCA2* mutations and platinum-resistant ovarian cancer, the RR was 33% in patients receiving olaparib 400 mg twice daily and 13% in patients receiving 100 mg twice daily [93]. Additional phase II studies of olaparib in recurrent serous ovarian cancer have confirmed favorable response in patients with and without *BRCA* mutations[94, 95].

PARP inhibitors are fairly well tolerated, with most common adverse events consisting of fatigue, nausea, and vomiting. Cognitive dysfunction and mood alterations have been described as a dose-limiting toxicity [93-96]. Dose reduction has been necessary in early trials combining PARP inhibitors with cytotoxic chemotherapy secondary to increased toxicity. Further, it is unclear if these agents outperform chemotherapy in germline *BRCA* mutation carriers. A randomized phase II trial comparing olaparib versus PLD in patients with *BRCA* mutations and progression within 12 months of platinum chemotherapy revealed higher RRs in the patients treated with olaparib. However, the primary endpoint of PFS was not reached, with only a slight improvement with olaparib (6.5 and 8.8 months for olaparib 200 and 400 mg, respectively, vs. 7.1 months for PLD; HR for combined doses, 0.88; 80% CI, 0.51-1.56; $P = 0.66$) [97].

The use of olaparib as a maintenance therapy in the platinum-sensitive recurrent setting was recently published with promising findings. Patients, who were not required to carry a germline mutation in *BRCA1* or *BRCA2*, were treated with olaparib or placebo until disease progression after any response to platinum agent. This phase II study found a clear improvement in PFS (HR, 0.35; 95% CI, 0.25-0.49; $P < 0.001$), with a toxicity profile consistent with previous studies [98]. Several ongoing phase II trials are evaluating olaparib in ovarian cancer, including its use in combination with carboplatin and paclitaxel in the recurrent platinum-sensitive setting (NCT01081951).

Several other PARP inhibitors are being evaluated in clinical trials for ovarian cancer. A phase II trial of iniparib (BSI-201, BiPar Sciences; South San Francisco, CA, USA) in combination with carboplatin and gemcitabine in platinum-sensitive ovarian cancer yielded

improved RR over historical RRs for chemotherapy alone (70.6% vs. 47.2%) [99]. Iniparib has also been evaluated in combination with carboplatin and gemcitabine in patients with platinum-resistant ovarian cancer. Among the first 19 evaluable patients in a single-arm phase II trial, this combination demonstrated a RR of 31.6% and median PFS of 5.9 months with no unexpected toxicities [100]. Additional studies of iniparib both as a single agent in patients with *BRCA1* or *BRCA2*-associated ovarian cancer are ongoing (NCT00677079). Interestingly, 2 recent publications reported that the antitumor activity of iniparib is not consistent with PARP inhibition, indicating a need for further preclinical assessment of this agent [101, 102]. Other PARP inhibitors are in early phase trials include MK-4827 (Merck & Co., Inc.; Whitehouse Station, NJ, USA), ABT-888 (Abbott Laboratories; Abbott Park, IL, USA), AG-14699 (rucaparib, Pfizer; New London, CT, USA), and BMN-673 (Biomarin; Novato, CA, USA).

There are patients with *BRCA* mutations that are resistant to PARP inhibition despite defects in base excision repair. Preclinical data indicate that resistance to this therapy is related to upregulation of other DNA repair pathways [103]. Additional proposed mechanisms of resistance to PARP inhibition are the loss of *BRCA2* mutations or development of secondary *BRCA2* mutations that restore *BRCA* function [104, 105].

Targeting the Phosphatidylinositol-3-kinase (PI3K)/Protein Kinase B (AKT)/Mammalian Target of Rapamycin (mTOR) Pathway

The PI3K pathway plays a key role in tumorigenesis through stimulation of several downstream mediators, including AKT. AKT acts on a variety of targets affecting cellular proliferation, survival, and evasion of apoptosis. mTOR is a critical target of AKT that subsequently activates proteins such as S6 kinase, impacting protein translation and progression of the cell cycle [106-108]. This pathway may be activated in ovarian cancers, serving as a potential mechanism of drug resistance [109]. Thus, inhibition of the PI3K pathway appears to be an attractive target for the treatment of ovarian cancer. Further, certain ovarian histology types such as low grade serous, clear cell, and endometrioid adenocarcinomas, are more likely to demonstrate aberrations in this pathway [110-112]. Thus, there is the potential for higher levels of clinical activity with appropriate patient selection during trial design.

PI3K inhibitors

First-generation PI3K inhibitors were largely unsuccessful in preclinical studies because of high toxicity, likely due to an absence of selectivity [106]. There are multiple PI3K inhibitors currently under exploration, although few have reached phase II clinical development. XL147 (Exelixis, Inc.; South San Francisco, CA, USA) is a reversible, highly selective PI3K inhibitor that has shown dose-dependent inhibition of the PI3K pathway in multiple tumor xenografts [106]. A phase I study of single-agent XL147 in patients with advanced solid tumors showed the agent had durable clinical benefit and was well tolerated, with skin rash being the most common drug-related toxicity [113]. An ongoing phase Ib/II trial (NCT00756847) is evaluating the combination of XL147 and paclitaxel and carboplatin in patients with advanced solid tumors; preliminary results suggest the combination is well

tolerated and induces tumor regression in a heavily pretreated patient population. Favorable responses in ovarian cancer have led to a dose expansion in this tumor type [114]. PX-866 (Oncothyreon Inc.; Seattle, WA, USA) is an irreversible PI3K inhibitor that has shown preclinical activity in ovarian cancer cell lines [115]. In a phase I (first-in-human) study, PX-866 was well tolerated, with adverse effects consisting primarily of grade 1/2 nausea, vomiting, and diarrhea [116]. Further phase I studies with PX-866 are ongoing in patients with advanced solid tumors.

mTOR inhibitors

mTOR may be considered the most important target of AKT, mediating the regulation of translation of different effectors involved in cell growth [106]. There are several agents of great interest that inhibit mTOR. Everolimus (Afinitor®, RAD001, Novartis Pharmaceuticals Corporation; East Hanover, NJ, USA) has shown preclinical activity in ovarian cancer models [117-119], and is currently being evaluated in phase II studies in combination with bevacizumab for patients with recurrent or persistent ovarian cancer (NCT00886691, NCT01031381). In addition, a phase I study evaluating everolimus plus carboplatin and PLD in relapsed ovarian cancer is ongoing (NCT01281514).

Temsirolimus (Torisel®, Pfizer; New London, CT, USA [formerly Wyeth]; Philadelphia, PA, USA) was evaluated in a phase I study in combination with topotecan in patients with advanced or recurrent gynecologic malignancies. This combination was well tolerated, with the dose-limiting toxicity of myelosuppression; 9 of 11 patients achieved SD at 8 weeks [120]. In an ongoing phase II trial combining temsirolimus with bevacizumab in recurrent ovarian cancer patients with up to 2 prior lines of therapy, there were 3 PRs and 14 patients progression free at 6 months among the first 25 enrolled patients. This trial has opened for second stage accrual [121]. A GOG phase II trial of single-agent temsirolimus for recurrent ovarian or primary peritoneal cancer reported an overall RR of 9.3% (5 PRs in 54 evaluable patients), 6-month PFS rate of 24.1%, and median PFS and OS of 3.2 months and 11.6 months, respectively. The investigators concluded that this activity, albeit modest, was insufficient to warrant further evaluation of temsirolimus in a phase III trial in an unselected population [122]. Additional phase II trials are currently evaluating temsirolimus in combination with PLD (NCT00982631) in relapsed ovarian cancer as well as temsirolimus in patients with platinum-refractory ovarian cancer (NCT01460979).

AKT inhibitors

Activation of downstream AKT is the most important PI3K function for onset and progression of tumor cells [106]. Furthermore, the inhibition of mTOR results in upregulation of AKT phosphorylation [123]. Thus, AKT is a rational target alone or in combination with other agents for ovarian cancer. Perifosine (Keryx Biopharmaceuticals, Inc; New York, NY, USA), an alkylphospholipid, is known to inhibit AKT by prevention of its recruitment to the cellular membrane. This agent has demonstrated activity in phase I studies in advanced solid tumors [124-126]. Results from a phase I study of perifosine in combination with docetaxel in patients with relapsed ovarian cancer suggest further study of the combination in patients with defined PI3K pathway mutational status is warranted [127]. MK-2206 (Merck & Co., Inc.; Whitehouse Station, NJ, USA), an allosteric inhibitor of Akt,

is now in phase II investigation for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer in a biomarker-assessed clinical trial (NCT01283035).

As noted above, the inhibition of only 1 target in the PI3K/AKT pathway may not be sufficient for an objective tumor response, given the extensive cross-talk and feedback loops found in this pathway. Furthermore, the PI3K/AKT pathway appears tightly linked to the retrovirus-associated DNA sequences (Ras)/v-raf 1 murine leukemia viral oncogene homolog 1 (Raf)/mitogen-activated protein kinase (MAPK) pathway that regulates cellular survival, proliferation, and avoidance of apoptosis. The Ras/Raf/MAPK pathway has been implicated in resistance to multiple targeted therapies, including those agents targeting the PI3K pathway [128]. For example, recent data demonstrate that cell lines with activating *Ras* mutations demonstrated resistance to everolimus in vitro [129]. Pairing drugs that target this pathway, such as mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors, with agents that target the PI3K pathway may be a rational way to overcome poor RRs and resistance. This combination was recently described in *KRAS*-mutated ovarian cancer cell lines and resulted in significant tumor regression [130]. To date, MEK inhibitors have not yet been explored in high-grade serous ovarian cancer, although preliminary activity in low-grade serous ovarian cancer was recently demonstrated for one agent (selumetinib [AZD6244], AstraZeneca; Wilmington, DE, USA) in a phase II trial (GOG-239) [131].

Targeting Src

Src is a downstream nonreceptor tyrosine kinase that mediates cancer cell growth, migration, adhesion, invasion, and angiogenesis [87, 132]. Overexpression of Src has been observed in ovarian cancer cell lines [133] and in late-stage cancers [134]. Src inhibition has been shown to reverse chemoresistance and enhance the activity of paclitaxel and platinum treatment in ovarian cancer cell lines [135, 136].

Dasatinib (Sprycel[®], Bristol-Myers Squibb Company; Princeton, NJ, USA) is a strong inhibitor of the Src family of kinases, as well as other targets at higher doses, including BCR-ABL, c-kit, and PDGF. Preclinical data strongly support further investigation of dasatinib as a single agent or in combination with chemotherapy in patients with ovarian cancer [137, 138]. A phase II study is evaluating dasatinib as monotherapy (NCT00671788) and a phase I study is evaluating dasatinib combined with paclitaxel and carboplatin (NCT00672295) for persistent or recurrent ovarian cancer.

Saracatinib (AZD0530, AstraZeneca; Wilmington, DE, USA) is an orally bioavailable inhibitor of Src. A phase II study of saracatinib plus carboplatin and paclitaxel versus chemotherapy alone in patients with platinum-sensitive ovarian cancer revealed a similar PFS (median, 8.3 vs. 7.8 months, respectively; HR, 0.99; 80% CI, 0.76-1.31) and overall RR (53.4% vs. 51.7%; HR, 0.91; 80% CI, 0.62-1.36) in both groups. The most common adverse events were neutropenia, febrile neutropenia, thrombocytopenia, and anemia, which were usually reported during the chemotherapy period [139]. An ongoing phase II study is evaluating saracatinib in advanced ovarian cancer (OVERT-1; NCT00610714) and a phase

II/III study in combination with weekly paclitaxel in platinum-resistant ovarian cancer has begun recruitment (NCT01196741).

Targeting Other Novel Pathways

Initial interest was high in the EGFR pathway in ovarian cancer secondary to the high but variable level of overexpression (4%-100%) found in this tumor type [140]. Activation of the EGFR pathway has impact on invasion and metastasis as well as cell survival through the PI3K/AKT and Ras/Raf pathways [141, 142]. Unfortunately, agents targeting this pathway have not demonstrated significant activity in ovarian cancer.

Several monoclonal antibodies targeting EGFR or another ErbB family member (e.g., cetuximab [Erbix[®], Bristol-Myers Squibb; New York, NY, USA], trastuzumab [Herceptin[®], Genentech; South San Francisco, CA, USA], lapatinib [Tykerb[®], GlaxoSmithKline; London, UK], pertuzumab [Genentech; South San Francisco, CA, USA]) and TKIs (e.g., erlotinib [Tarceva[®], Genentech; South San Francisco, CA, USA], gefitinib [Iressa[®], AstraZeneca; Wilmington, DE, USA]) have been investigated in ovarian cancer, but have demonstrated only minimal activity as monotherapy or in combination with standard chemotherapy [143-156]. This may be secondary to recent data that indicate that response to EGFR-directed therapy is related to mutations in *EGFR*, which are rare in ovarian cancer, rather than overexpression of EGFR [157]. Despite weak evidence supporting the benefit of inhibiting EGFR, the European Organization for Research and Treatment of Cancer (EORTC) has recently completed enrollment of a phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platinum-based therapy (EORTC 55041; NCT00263822).

One alternative strategy in this pathway is based on efforts to block EGFR activation through prevention of specific receptor dimerizations. One agent, MM-121 (Merrimack Pharmaceuticals Inc.; Cambridge, MA, USA), which is designed to block dimerization of ErbB3, has shown promising preclinical and phase I data [158], which is supporting a randomized phase II trial in combination with weekly paclitaxel for platinum-resistant/refractory advanced ovarian cancer (NCT01447706).

The agent vandetanib is a TKI that has dual action on VEGFR-2 and EGFR to target angiogenesis and cellular survival mechanisms. Unfortunately, a study of vandetanib as a single agent for recurrent ovarian cancer had no activity, resulting in study closure after first stage accrual. Molecular testing that was performed on tissues after treatment was significant for blockage of the EGFR pathway but had no impact on VEGFR [159]. Based on preclinical studies that indicated enhanced activity of antivasculature therapy in combination with docetaxel [160], a trial combining docetaxel with vandetanib is now underway for the treatment of recurrent ovarian cancer (NCT00872989).

Folate receptor alpha (α -FR) is involved with folate transport and binds the folate receptor with high affinity. This is an attractive target in ovarian cancer, as greater than 70% of primary and 82% of recurrent ovarian tumors overexpress α -FR [161]. Farletuzumab (MORAb-003, Morphotek, Inc.; Exton, PA, USA), a humanized monoclonal antibody against α -FR, was generally safe and well tolerated in a phase I study of heavily pretreated

patients with ovarian cancer. There were no severe adverse events; the majority of toxicity was mild including hypersensitivity, fatigue, and diarrhea [162]. In addition, a phase II study of farletuzumab alone with subsequent addition of carboplatin and taxane at the time of disease progression in patients with platinum-sensitive ovarian cancer in first relapse had promising results. Approximately 90% of patients receiving combination therapy achieved normalized CA125 and approximately 70% had a response. Farletuzumab was well tolerated as a single agent, with no additive toxicity combined with chemotherapy [163]. A phase III randomized, double-blind, placebo-controlled study was performed to farletuzumab in combination with weekly paclitaxel in patients with platinum-resistant or refractory ovarian cancer (NCT00738699) [164]. Unfortunately, this study was closed to accrual after failure to meet predefined efficacy endpoints at interim analysis. This agent is currently under evaluation in combination with carboplatin and taxane in an ongoing phase III study in patients with platinum-sensitive ovarian cancer in first relapse (NCT00849667). EC145 (Endocyte, Inc.; West Lafayette, IN) is a conjugate of folic acid and desacetylvinblastine that binds to the folate receptor with high affinity. This agent demonstrated a significant improvement in PFS in combination with PLD (21.7 weeks) compared to PLD alone (11.7 weeks) in patients with platinum-resistant ovarian cancer in a phase II trial [165], prompting an ongoing randomized phase III trial (NCT01170650).

Activity of the insulin-like growth factor (IGF) family impacts cell proliferation and tumorigenesis among many solid tumors, including ovarian cancer [166, 167]. IGF can activate the PI3K/AKT pathway leading to cellular survival and metastasis [166]. Microarray studies have demonstrated that upregulation of this pathway correlates with poor OS in ovarian cancer [168]. Currently, a humanized monoclonal antibody that targets the IGF-1 receptor, AMG 479 (Amgen Inc.; Thousand Oaks, CA, USA), is under exploration as a single agent in platinum-sensitive ovarian cancer (NCT00719212) and in combination with standard cytotoxics as first-line therapy (NCT00718523). In addition, a dual IGF and PI3K/Akt/mTOR blockade strategy is being pursued with dalotuzumab (Merck & Co., Inc.; Whitehouse Station, NJ, USA) in combination with either an mTOR inhibitor or an Akt inhibitor (either ridaforolimus or MK-2206, respectively [both also Merck & Co, Inc]) in advanced malignancies, with preliminary antitumor activity to be assessed in a subgroup of patients with metastatic or recurrent platinum-resistant ovarian cancer (NCT01243762).

Serous ovarian cancer is characterized by near universal aberration in the P53 tumor suppressor gene [169]. Normally p53 plays an important role as a cell cycle checkpoint regulator, particularly at the G1 checkpoints. While protecting normal cells from DNA injury, this regulator mechanism can also allow tumor cells to repair induced DNA damage—thereby reducing the effectiveness of chemotherapy. Cells that lack normal p53 function are known to rely on other checkpoints for cell cycle regulation. Wee-1 is a tyrosine kinase that regulates the G2 cell cycle checkpoint. It gains prominence when p53 function is perturbed. As inhibition of Wee-1 in p53-deficient tumors leads to reduced capacity for tumor cell repair of induced DNA damage (e.g., chemotherapy, radiation) [170], it represents a potential target for p53-mutant ovarian cancer. Accordingly, a randomized, placebo-controlled phase II study is evaluating paclitaxel and carboplatin with or without the Wee-1 tyrosine kinase inhibitor MK-1775 (Merck & Co, Inc; Whitehouse Station, NJ, USA) in women with p53 mutation-positive platinum-sensitive recurrent ovarian cancer.

Conclusions

Given the limited success of traditional cytotoxic chemotherapy in the treatment of ovarian cancer, recent clinical studies have focused more heavily on molecular targeted therapy. There are a number of promising pathways in ovarian cancer that may prove to advance OS while minimizing quality of life impact. Current study designs will continue to clarify the role of these agents, specifically use in the upfront versus recurrent settings, as well as development of rational combinations to overcome resistance. Certainly, close analysis of factors that predict adverse events of these agents will be necessary as our knowledge continues to expand.

Acknowledgments

This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Writing and editorial assistance was provided by Lisa Shannon, PharmD, of MedErgy, which was contracted by BIPI for these services. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), were fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development. The authors received no compensation related to the development of the manuscript.

References

1. American Cancer Society. Cancer Facts & Figures, 2012. American Cancer Society; Atlanta, GA: 2012.
2. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. *Gynecol Oncol*. 2010; 117:152–158. [PubMed: 20056266]
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med*. 1996; 334:1–6. [PubMed: 7494563]
4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med*. 2006; 354:34–43. [PubMed: 16394300]
5. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet*. 2009; 374:1331–1338. [PubMed: 19767092]
6. National Comprehensive Cancer Network. [Accessed 8 February 2012] NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer. Including Fallopian Tube Cancer and Primary Peritoneal Cancer. 2012. V.2.2012. http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf
7. Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. *Baillieres Best Pract Res Clin Obstet Gynaecol*. 2000; 14:901–918. [PubMed: 11141340]
8. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. *Angiogenesis*. 2005; 8:169–182. [PubMed: 16211363]
9. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. *Gynecol Oncol*. 2004; 94:630–635. [PubMed: 15350351]
10. Delli Carpini J, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. *Angiogenesis*. 2010; 13:43–58. [PubMed: 20229258]
11. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spanuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. *Clin Cancer Res*. 2007; 13:7487–7495. [PubMed: 18094433]

12. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. *Ann Surg Oncol*. 1999; 6:373–378. [PubMed: 10379858]
13. Kaye SB. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? *J Clin Oncol*. 2007; 25:5150–5152. [PubMed: 18024860]
14. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. *Br J Cancer*. 2009; 100:1–7. [PubMed: 19002176]
15. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. *J Clin Oncol*. 2007; 25:5180–5186. [PubMed: 18024865]
16. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. *J Clin Oncol*. 2007; 25:5165–5171. [PubMed: 18024863]
17. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. *J Clin Oncol*. 2008; 26:76–82. [PubMed: 18165643]
18. del Carmen MG, Micha JP, Small LA, Street DG, Londhe A, McGowan T. Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study. *J Clin Oncol*. 2011; 29 Abstract 5061.
19. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol*. 2012
20. Sanchez-Munoz A, Mendiola C, Perez-Ruiz E, Rodriguez-Sanchez CA, Jurado JM, Onso-Carrion L, Ghanem I, de VG, Quero-Blanco C, Alba E. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. *Oncology*. 2010; 79:98–104. [PubMed: 21079407]
21. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, Goff BA, Gray HJ, Malpass TW. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a Phase 2 Study. *Cancer*. 2011; 117:3731–3740. [PubMed: 21815133]
22. Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, Watanabe A, Kato M, Goto T, Kikuchi Y. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. *Gynecol Oncol*. 2011; 122:233–237. [PubMed: 21601912]
23. Tillmanns TD, Lowe MP, Schwartzberg LS, Walker MS, Stepanski EJ. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. *J Clin Oncol*. 2010; 28 Abstract 5009.
24. Wenham R, LaPolla J, Lin H, Apte S, Roberts W, Lancaster J, Theodore S, Fabri D, Havrilesky L, Alvarez-Secord A. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. *Gynecol Oncol*. 2010; 116:S61–S62. Abstract 155.
25. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. *Gynecol Oncol*. 2008; 110:49–55. [PubMed: 18423560]
26. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, Lopez KL, Nickle M, Brown JV III. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. *Int J Gynecol Cancer*. 2007; 17:771–776. [PubMed: 17343605]
27. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin,

- paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. *J Clin Oncol.* 2010; 28:154–159. [PubMed: 19917843]
28. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med.* 2011; 365:2473–2483. [PubMed: 22204724]
 29. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du BA, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med.* 2011; 365:2484–2496. [PubMed: 22204725]
 30. Perren T, Swart AM, Pfisterer J, Ledermann J, Lortholary A, Kristensen G, Carey M, Beale P, Cervantes A, Oza A. on behalf of GCIG ICON7 collaborators. ICON7: A phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). *Ann Oncol.* 2010; 21:viii2–3. Abstract LBA4.
 31. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. *J Clin Oncol.* 2010; 28:207–214. [PubMed: 19949018]
 32. Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Oncol.* 2012; 13:154–162. [PubMed: 22192729]
 33. Tew WP, Colombo N, Ray-Coquard I, Oza A, del Campo J, Scambia G, Spriggs D. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. *J Clin Oncol.* 2007; 25 Abstract 5508.
 34. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. *Lancet Oncol.* 2011; 12:1109–1117. [PubMed: 21992853]
 35. Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. *Drug Resist Updat.* 2009; 12:74–80. [PubMed: 19394890]
 36. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer.* 2008; 8:592–603. [PubMed: 18650835]
 37. Grepin R, Pages G. Molecular mechanisms of resistance to tumour anti-angiogenic strategies. *J Oncol.* 2010; 2010:835680. [PubMed: 20224655]
 38. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. *Cancer Res.* 1993; 53:4550–4554. [PubMed: 8402626]
 39. Apte SM, Bucana CD, Killian JJ, Gershenson DM, Fidler IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. *Gynecol Oncol.* 2004; 93:78–86. [PubMed: 15047217]
 40. Dabrow MB, Francesco MR, McBrearty FX, Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. *Gynecol Oncol.* 1998; 71:29–37. [PubMed: 9784315]
 41. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. *Am J Obstet Gynecol.* 2008; 198:477–479. [PubMed: 18395047]
 42. Matei D, Emerson RE, Lai YC, Baldrige LA, Rao J, Yiannoutsos C, Donner DD. Autocrine activation of PDGFR α promotes the progression of ovarian cancer. *Oncogene.* 2006; 25:2060–2069. [PubMed: 16331269]

43. Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. *Hum Pathol.* 2005; 36:242–249. [PubMed: 15791568]
44. Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW. PDGF BB induces VEGF secretion in ovarian cancer. *Cancer Biol Ther.* 2007; 6:1951–1959. [PubMed: 18075302]
45. Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF, Eidsvoog K. Basic fibroblast growth factor and receptor expression in human ovarian cancer. *Gynecol Oncol.* 1994; 55:277–284. [PubMed: 7959296]
46. Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, Jaffe RB. Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. *Am J Obstet Gynecol.* 1993; 169:1517–1523. [PubMed: 8267056]
47. Fujimoto J, Ichigo S, Hori M, Hirose R, Sakaguchi H, Tamaya T. Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. *Eur J Gynaecol Oncol.* 1997; 18:349–352. [PubMed: 9378151]
48. Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. *Oncogene.* 2001; 20:5878–5887. [PubMed: 11593393]
49. Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, Gallagher JT, Jayson GC. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. *Clin Cancer Res.* 2005; 11:4282–4288. [PubMed: 15958608]
50. Valve E, Martikainen P, Seppanen J, Oksjoki S, Hinkka S, Anttila L, Grenman S, Klemi P, Harkonen P. Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. *Int J Cancer.* 2000; 88:718–725. [PubMed: 11072239]
51. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. *Development.* 1998; 125:1591–1598. [PubMed: 9521897]
52. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. *FASEB J.* 2004; 18:338–340. [PubMed: 14657001]
53. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. *Cancer Cell.* 2005; 8:299–309. [PubMed: 16226705]
54. Batchelor TT, Sorensen AG, di TE, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell.* 2007; 11:83–95. [PubMed: 17222792]
55. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. *J Clin Invest.* 2003; 111:1287–1295. [PubMed: 12727920]
56. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivasculature therapy for ovarian carcinoma. *Clin Cancer Res.* 2007; 13:4209–4217. [PubMed: 17634550]
57. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. *Hum Reprod.* 2006; 21:262–268. [PubMed: 16172144]
58. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2

- tyrosine kinase inhibitor for the treatment of cancer. *Cancer Res.* 2005; 65:4389–4400. [PubMed: 15899831]
59. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. *J Clin Oncol.* 2009; 27:5601–5606. [PubMed: 19826113]
 60. Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ, Wang L, McGill S, Ivy SP, Oza AM. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. *J Clin Oncol.* 2008; 26 Abstract 5521.
 61. Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, Ledermann JA. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. *Br J Cancer.* 2011
 62. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. *Cancer Res.* 2008; 68:4774–4782. [PubMed: 18559524]
 63. du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt VL, Harter P. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. *Ann Oncol.* 2010; 21:370–375. [PubMed: 19889612]
 64. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. *J Clin Oncol.* 2011; 29:3798–3804. [PubMed: 21859991]
 65. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. *Curr Opin Investig Drugs.* 2008; 9:1324–1335.
 66. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Bolor A, Stafford JA, Luttrell DK, Cheung M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. *Mol Cancer Ther.* 2007; 6:2012–2021. [PubMed: 17620431]
 67. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. *Gynecol Oncol.* 2010; 119:32–37. [PubMed: 20584542]
 68. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res.* 2004; 64:7099–7109. [PubMed: 15466206]
 69. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. *J Clin Oncol.* 2011; 29:69–75. [PubMed: 21098323]
 70. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. *J Clin Oncol.* 2008; 26:3709–3714. [PubMed: 18669456]
 71. Kohn EC, Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA, Kotz HL, Squires J, Houston ND, Chen HX, Wright JJ. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naïve epithelial ovarian cancer (EOC) patients. *J Clin Oncol.* 2011; 29 Abstract 5019.

72. Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, Jones T, Sutton G, Matei D. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. *Gynecol Oncol.* 2011; 123:499–504. [PubMed: 21955480]
73. Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, Macalpine K, Wright JJ, Oza AM. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. *Int J Gynecol Cancer.* 2010; 20:787–793. [PubMed: 20847613]
74. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. *J Med Chem.* 2003; 46:1116–1119. [PubMed: 12646019]
75. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. *Mol Cancer Ther.* 2003; 2:471–478. [PubMed: 12748309]
76. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. *J Clin Endocrinol Metab.* 2006; 91:4070–4076. [PubMed: 16849418]
77. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin Cancer Res.* 2003; 9:327–337. [PubMed: 12538485]
78. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. *Blood.* 2003; 101:3597–3605. [PubMed: 12531805]
79. Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburger A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. *Ann Oncol.* 2012
80. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP, Eisenhauer EA. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. *Ann Oncol.* 2011; 22:335–340. [PubMed: 20705911]
81. Campos S, Penson R, Berlin S, Matulonis U, Horowitz N. A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma. *Gynecol Oncol.* 2010; 116:S119–S120. Abstract 306.
82. Buckanovich RJ, Berger R, Sella A, Sikic BI, Shen X, Ramies DA, Smith DC, Vergote IB. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). *J Clin Oncol.* 2011; 29 Abstract 5008.
83. Schreiber V, Dantzer F, Ame JC, de MG. Poly(ADP-ribose): novel functions for an old molecule. *Nat Rev Mol Cell Biol.* 2006; 7:517–528. [PubMed: 16829982]
84. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. *Nucleic Acids Res.* 2003; 31:4959–4964. [PubMed: 12930944]
85. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. *J Clin Oncol.* 2008; 26:3785–3790. [PubMed: 18591545]

86. Iglehart JD, Silver DP. Synthetic lethality--a new direction in cancer-drug development. *N Engl J Med*. 2009; 361:189–191. [PubMed: 19553640]
87. Ledermann JA, Raja FA. Targeted trials in ovarian cancer. *Gynecol Oncol*. 2010; 119:151–156. [PubMed: 20591473]
88. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet*. 2001; 68:700–710. [PubMed: 11179017]
89. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. *J Mol Med (Berl)*. 2006; 84:16–28. [PubMed: 16283147]
90. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. *J Clin Oncol*. 2010; 28:3570–3576. [PubMed: 20606085]
91. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. *Cancer Res*. 2000; 60:5329–5333. [PubMed: 11034065]
92. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. *J Clin Oncol*. 2010; 28:3555–3561. [PubMed: 20547991]
93. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*. 2010; 376:245–251. [PubMed: 20609468]
94. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol*. 2011; 12:852–861. [PubMed: 21862407]
95. Ang J, Yap TA, Fong P, et al. Preliminary experience with use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). *J Clin Oncol*. 2010; 28 Abstract 5041.
96. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*. 2009; 361:123–134. [PubMed: 19553641]
97. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. *J Clin Oncol*. 2012; 30:372–379. [PubMed: 22203755]
98. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med*. 2012; 366:1382–1392. [PubMed: 22452356]
99. Penson RT, Whalen C, Lasonde B, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. *J Clin Oncol*. 2011; 29 Abstract 5004.
100. Birrer MJ, Konstantinopoulos P, Penson RT, Roche M, Ambrosio A, Stallings TE, Matulonis U, Bradley CR. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. *J Clin Oncol*. 2011; 29

101. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. *Clin Cancer Res.* 2012; 18:1655–1662. [PubMed: 22291137]
102. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Lador US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF, Shoemaker AR. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor. *Clin Cancer Res.* 2012; 18:510–523. [PubMed: 22128301]
103. Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, Zhu GD, Penning T, Rosenberg S, Giranda VL, Luo Y, Levenson J, Johnson EF, Shoemaker AR. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. *Mol Cancer Res.* 2009; 7:1686–1692. [PubMed: 19825992]
104. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. *Nature.* 2008; 451:1111–1115. [PubMed: 18264088]
105. Ashworth A. Drug resistance caused by reversion mutation. *Cancer Res.* 2008; 68:10021–10023. [PubMed: 19074863]
106. Mazzeletti M, Brogini M. PI3K/AKT/mTOR inhibitors in ovarian cancer. *Curr Med Chem.* 2010; 17:4433–4447. [PubMed: 21062259]
107. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov.* 2005; 4:988–1004. [PubMed: 16341064]
108. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. *J Clin Oncol.* 2009; 27:2278–2287. [PubMed: 19332717]
109. Altomare DA, Wang HQ, Skele KL, De RA, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. *Oncogene.* 2004; 23:5853–5857. [PubMed: 15208673]
110. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, Timorek A, nsonka-Mieszkowska A, Kupryjanczyk J. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. *Cancer Biol Ther.* 2009; 8:21–26. [PubMed: 19029838]
111. Romero I, Bast RC Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. *Endocrinology.* 2012; 153:1593–1602. [PubMed: 22416079]
112. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. *Cancer Res.* 1998; 58:2095–2097. [PubMed: 9605750]
113. Edelman G, Bedell C, Shapiro G, Pandya SS, Kwak EL, Scheffold C, Nguyen LT, Laird A, Baselga J, Rodon J. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced solid tumors. *J Clin Oncol.* 2010; 28 Abstract 3004.
114. Traynor AM, Kurzrock R, Bailey HH, Attia S, Scheffold C, van Leeuwen B, Wu B, Falchook GS, Moulder SL, Wheler J. A phase I safety and pharmacokinetic (PK) study of PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. *J Clin Oncol.* 2010; 28 Abstract 3078.
115. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. *Mol Cancer Ther.* 2004; 3:763–772. [PubMed: 15252137]
116. Jimeno A, Herbst RS, Falchook GS, Messersmith WA, Hecker S, Peterson S, Hausman DF, Kurzrock R, Eckhardt SG, Hong DS. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. *J Clin Oncol.* 2010; 28 Abstract 3089.
117. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. *Cancer Res.* 2007; 67:2408–2413. [PubMed: 17363557]

118. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. *Clin Cancer Res.* 2007; 13:4261–4270. [PubMed: 17634556]
119. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. *Clin Cancer Res.* 2009; 15:5404–5413. [PubMed: 19690197]
120. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. *Gynecol Oncol.* 2010; 117:473–476. [PubMed: 20347480]
121. Morgan R, Oza AM, Qin R, Laumann KM, Mackay H, Strevel EL, Welch S, Sullivan D, Wenham RM, Chen HX, Doyle LA, Gandara DR, Erlichman C. A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset-A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCC) N01 Consortia NCI#8233. *J Clin Oncol.* 2011; 29 Abstract 5015.
122. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2011; 123:19–26. [PubMed: 21752435]
123. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res.* 2006; 66:1500–1508. [PubMed: 16452206]
124. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzooonian R, Alberti D, Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. *Clin Cancer Res.* 2004; 10:7450–7456. [PubMed: 15569974]
125. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. *Mol Cancer Ther.* 2003; 2:1093–1103. [PubMed: 14617782]
126. Engel JB, Schonhals T, Hausler S, Krockenberger M, Schmidt M, Horn E, Koster F, Dietl J, Wischhusen J, Honig A. Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. *Arch Gynecol Obstet.* 2010; 283:603–610. [PubMed: 20405296]
127. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. *Gynecol Oncol.* 2012
128. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Basecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. *Cell Cycle.* 2010; 9:1781–1791. [PubMed: 20436278]
129. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. *J Clin Invest.* 2010; 120:2858–2866. [PubMed: 20664172]
130. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA. In vivo activity of combined PI3K/mTOR and MEK-inhibition in a KrasG12D:Pten deletion mouse model of ovarian cancer. *Mol Cancer Ther.* 2011; 10:1440–1449. [PubMed: 21632463]

131. Farley J, Brady W, Birrer M, Lankes H, Coleman R, Morgan M, Mannel R, Yamada D, Mutch D, Gershenson D. A phase II trial of AZD6244 in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. *Int J Gynaecol Cancer*. 2011; 21:38.
132. Blagden S, Gabra H. Promising molecular targets in ovarian cancer. *Curr Opin Oncol*. 2009; 21:412–419. [PubMed: 19553815]
133. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC Jr, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. *Clin Cancer Res*. 1999; 5:2164–2170. [PubMed: 10473101]
134. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. *Gynecol Oncol*. 2003; 88:73–79. [PubMed: 12504632]
135. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. *Mol Cancer Ther*. 2005; 4:217–224. [PubMed: 15713893]
136. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. *Biochem Biophys Res Commun*. 2003; 309:377–383. [PubMed: 12951060]
137. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. *Br J Cancer*. 2009; 101:1699–1708. [PubMed: 19861960]
138. Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK, Secord AA. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. *Gynecol Oncol*. 2011
139. Poole C, Lisyanskaya A, Rodenhuis S, Kristensen G, Pujade-Lauraine E, Cantarini M, Emeribe U, Stuart M, Ray-Coquard I. A randomized phase II clinical trial of the Src inhibitor saracatinib (AZD0530) and carboplatin + paclitaxel (C + P) versus C + P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC). *Ann Oncol*. 2010; 21:viii304. Abstract 9720.
140. Lafky JM, Wilken JA, Baron AT, Mailhe NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. *Biochim Biophys Acta*. 2008; 1785:232–265. [PubMed: 18291115]
141. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. *Oncogene*. 2000; 19:6550–6565. [PubMed: 11426640]
142. Normanno N, De LA, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De FG, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene*. 2006; 366:2–16. [PubMed: 16377102]
143. Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. *Cancer*. 2007; 109:1323–1330. [PubMed: 17330838]
144. Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. *Int J Gynecol Cancer*. 2005; 15:785–792. [PubMed: 16174225]
145. Mavroudis D, Efsthathiou E, Polyzos A, Athanasiadis A, Milaki G, Kastritis E, Kalykaki A, Saridaki Z, Dimopoulos A, Georgoulis V. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC). *J Clin Oncol*. 2004; 22
146. Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhomme C. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). *Gynecol Oncol*. 2010; 116:157–162. [PubMed: 20109725]
147. Vasey PA, Gore M, Wilson R, Rustin G, Gabra H, Guastalla JP, Lauraine EP, Paul J, Carty K, Kaye S. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. *Br J Cancer*. 2008; 98:1774–1780. [PubMed: 18506181]

148. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. *J Clin Oncol.* 2003; 21:283–290. [PubMed: 12525520]
149. Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, Matei DE, Koch KM, Alvarez RD. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. *Gynecol Oncol.* 2008; 111:95–101. [PubMed: 18692224]
150. Joly F, Weber B, Pautier P, Fabbro M, Selle F, Krieger S, Leconte A, Bourgeois H, Henry-Amar M. Combined topotecan and lapatinib in patients with early recurrent ovarian and peritoneal cancer after first line of platinum-based chemotherapy: a French FEDEGYN-FNCLCC Phase II trial. *J Clin Oncol J Clin Oncol.* 2009; 27 Abstract 5555.
151. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. *Gynecol Oncol.* 2009; 113:21–27. [PubMed: 19162309]
152. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. *Gynecol Oncol.* 2008; 110:140–145. [PubMed: 18554700]
153. Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2008; 108:493–499. [PubMed: 18191993]
154. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. *J Clin Oncol.* 2006; 24:4324–4332. [PubMed: 16896006]
155. Kaye SB, Poole CJ, Bidzinski M, Gianni L, Gorbunova V, Novikova E, Strauss A, McNally VA, Ross G, Vergote I. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. *J Clin Oncol.* 2008; 26 Abstract 5520.
156. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. *J Clin Oncol.* 2010; 28:1215–1223. [PubMed: 19901115]
157. Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M, Montironi R, Lopez-Beltran A. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. *Future Oncol.* 2011; 7:519–541. [PubMed: 21463141]
158. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. *Cancer Res.* 2010; 70:2485–2494. [PubMed: 20215504]
159. Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. *Clin Cancer Res.* 2010; 16:664–672. [PubMed: 20068097]
160. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. *Cancer Res.* 2007; 67:281–288. [PubMed: 17210709]

161. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. *Gynecol Oncol.* 2008; 108:619–626. [PubMed: 18222534]
162. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander EN, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. *Clin Cancer Res.* 2010; 16:5288–5295. [PubMed: 20855460]
163. White AJ, Coleman RL, Armstrong DK, Glenn D, Bicher A, Richards DA, Schneeweiss A, Old LJ, Schweizer C, Weil S. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study. *J Clin Oncol.* 2010; 28 Abstract 5001.
164. Elit L, Konner JA, Armstrong DK, Buck M, Dean A, Finkler NJ, Hulstine A, Schweizer C, Phillips M, Weil S. A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. *J Clin Oncol.* 2010; 28 Abstract TPS255.
165. Naumann RW, et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. *J Clin Oncol.* 2011; 29:343s. Abstract 5045.
166. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. *Lancet Oncol.* 2002; 3:298–302. [PubMed: 12067807]
167. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. *Endocrinology.* 2002; 143:3259–3267. [PubMed: 12193537]
168. Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. *Endocr Relat Cancer.* 2007; 14:781–790. [PubMed: 17914107]
169. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature.* 2011; 474:609–615. [PubMed: 21720365]
170. Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. *Curr Clin Pharmacol.* 2010; 5:186–191. [PubMed: 20406171]

Figure 1. Key angiogenic targets in ovarian cancer

AKT, protein kinase B; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; Flt-3, fms-like tyrosine kinase-3; mTOR, mammalian target of rapamycin; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3-kinase; Raf, v-raf 1 murine leukemia viral oncogene homolog 1; RET, rearranged during transfection; src, v-src sarcoma viral oncogene homolog; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

Table 1
Targeted Investigational Agents in Development for Ovarian Cancer

Investigational agent	Target(s)	Phase of development in ovarian cancer
Bevacizumab	VEGF	III
Aflibercept (VEGF-Trap)	VEGF	III
Cediranib	VEGFR-1, -2, -3, PDGFR- α/β , FGFR-1, c-kit	III
Nintedanib (BIBF 1120)	VEGFR-1, -2, -3, PDGFR- α/β , FGFR-1, -2, -3, Src family, Flt-3	III
Pazopanib	VEGFR-1, -2, -3, PDGFR- α/β , FGFR-1, -3, c-kit	III
Sorafenib	VEGFR-2, -3, PDGFR- β , c-kit, Flt-3, Raf	II
Sunitinib	VEGFR-2, PDGFR- β , c-kit, Flt-3, RET	II
Cabozantinib (XL184)	VEGFR-2, c-kit, RET, MET	II
Olaparib (AZD2281)	PARP	II
Iniparib (BSI-201)	PARP	II
MK-4827	PARP	I
ABT-888	PARP	I/II
XL147	PI3K	I/II (advanced solid tumors; endometrial cancer)
PX-866	PI3K	I (advanced solid tumors)
Everolimus	mTOR	II
Temsirolimus	mTOR	II
Perifosine	AKT	I
Dasatinib	Src	II
Saracatinib (AZD0530)	Src	II/III
Erlotinib	EGFR	III
MM-121	EGFR (ErbB3)	II
Vandetanib	VEGFR-2, EGFR	II
Farletuzumab (MORab-003)	α -FR	III
AMG 479	IGF-1	II

α -FR, alpha folate receptor; AKT, protein kinase B; c-kit, stem cell factor receptor; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; Flt-3, fms-like tyrosine kinase-3; IGF-1, insulin-like growth factor 1; MET, mesenchymal-epithelial transition; mTOR, mammalian target of rapamycin; PARP, poly-ADP-ribose polymerase; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3-kinase; Raf, v-raf 1 murine leukemia viral oncogene homolog 1; RET, rearranged during transfection; src, v-src sarcoma viral oncogene homolog; VEGFR, vascular endothelial growth factor receptor.

Table 2
Efficacy and Safety in Phase II/III Trials of Antiangiogenic Agents in Combination With Chemotherapy

Trial	Setting	Treatment	RR, %	SD, %	Outcomes	Reported grade 3 to 4 AEs
Bevacizumab – relapsed/refractory						
Garcia [17]; phase II (N = 70) ^a	Recurrent EOC/PPC; 3 prior regimens	Bev + cyclo	24 (PR)	63	TTP, 7.2 mo. OS, 16.9 mo.	Hypertension, proteinuria
del Carmen [18]; phase II (N = 54) ^b	Recurrent EOC/PPC/FTC; relapse-free interval >6 mo. after first-line platinum regimen	Bev + carbo/PLD	72 (NR)	NR	PFS, 14.1 mo.	Blood/lymphatic system, gastrointestinal, vascular disorders, hand-foot syndrome, DVT, and small intestinal perforation
McGonigle [21]; phase II (N = 40)	Recurrent OC/PPC; 2 prior regimens	Bev + topo	25 (PR)	35	PFS, 7.8 mo. OS, 16.6 mo.	Hypertension, neutropenia, gastrointestinal toxicity, pain, metabolic toxicity, bowel obstruction, cardiotoxicity
Kudoh [22]; phase II (N = 30)	Recurrent EOC; 1 prior regimen	Bev + PLD	7 (CR); 27 (PR)	40	PFS, 6 mo.	Hand-foot syndrome, GIP
Tillmans [23]; phase II (N = 48) ^b	Recurrent EOC/PPC; 1 prior regimen	Bev + nab-pac	46.1 (PR)	30.8	PFS, 8.3 mo. OS, 16.5 mo.	NR
Wenham [24]; phase II (N = 27) ^b	Recurrent OC; 3 prior regimens	Bev + doc	5 (CR); 53 (PR)	37	PFS, 21% at 6 mo.	Leukopenia, neutropenia, infection, fatigue, anorexia, rash, metabolic fistula, GIP
OCEANS [19]; phase III (N = 484)	Recurrent platinum-sensitive EOC/PPC/FTC; 1 prior regimen	Carbo/gem vs. carbo/gem + bev → bev	57.4 vs. 78.5 (P <0.0001)	NR	PFS, 8.4 vs. 12.4 mo. OS, 35.2 vs. 33.3 mo. ^c	Neutropenia, hypertension, proteinuria, bleeding (non-CNS), venous thrombotic event, left ventricular dysfunction/congestive heart failure, wound healing complication ^d
Bevacizumab – first line						
Micha [26]; phase II (N = 18)	Chemonaive advanced EOC/PPC/FTC	Bev + pac/carbo	30 (CR); 50 (PR)	5	NR	Neutropenia, hypertension, neuropathy
Penson [27]; phase II (N = 62)	Chemonaive EOC/FTC/PPC/UPC	Bev + pac/carbo → bev maintenance	21 (CR); 55 (PR)	21	PFS, 29.8 mo.	Hypertension, musculoskeletal pain, proteinuria, metabolic, thrombocytopenia

Trial	Setting	Treatment	RR, %	SD, %	Outcomes	Reported grade 3 to 4 AEs
GOG 218 [28]; phase III (N = 1,873)	Chemonaive EOC/PPC/FTC	Pac/carbo vs. bev + pac/carbo vs. bev maintenance	NR	NR	PFS, 10.3 vs. 11.2 (HR = 0.908; 95% CI, 0.795-1.040; <i>P</i> = 0.16) vs. 14.1 mo. (HR = 0.717; 95% CI, 0.625-0.824; <i>P</i> < 0.001) OS, 39.3 vs. 38.7 (HR = 1.036; 95% CI, 0.827-1.297; <i>P</i> = 0.76) vs. 39.7 mo. (HR = 0.915; 95% CI, 0.727-1.152; <i>P</i> = 0.45)	Proteinuria, neutropenia, non-CNS bleeding (other AEs were reported based on grade 2 or all-grade incidences)
ICON7 [29]; phase III (N = 1,528)	Chemonaive EOC/PPC/FTC	Pac/carbo vs. bev + pac/carbo → bev maintenance	48 vs. 67 (<i>P</i> < 0.001)	46% vs. 29%	PFS, HR = 0.81 (95% CI, 0.70-0.94); <i>P</i> = 0.004 favoring bev arm OS, HR = 0.85 (95% CI, 0.69-1.04); <i>P</i> = 0.11	Bleeding, abscess and fistula, GIP, hypertension, proteinuria, thromboembolic event, neutropenia, febrile neutropenia, thrombocytopenia, congestive heart failure, wound healing complication
Aflibercept						
Coleman [34]; phase II (N = 46)	Recurrent EOC/PPC/FTC; 2 prior regimens	Aflibercept + doc	54	24	PFS, 6.4 mo. OS, 26.6 mo.	Neutropenia, leukopenia, fatigue, dyspnea, stomatitis, reduced magnesium, elevated creatinine, GIP, sensory neuropathy, TIA, headache
Sorafenib						
Ramasubbaiah [72]; phase I/II (N = 30)	Platinum-resistant EOC/PPC	Sorafenib + topo	16.7 (PR)	46.7	PFS, 3.7 mo. OS, 14.0 mo.	Neutropenia, thrombocytopenia, anemia, fatigue, nausea, vomiting
Welch [73]; phase II (N = 43)	Platinum-refractory EOC	Sorafenib + gem	4.7 (PR)	18.3	TTP, 5.4 mo. OS, 13.0 mo.	Lymphopenia, neutropenia, thrombocytopenia, hand-foot syndrome, fatigue, hypokalemia, diarrhea

AEs, adverse events; bev, bevacizumab; carbo, carboplatin; CI, confidence interval; CNS, central nervous system; cyclo, cyclophosphamide; doc, docetaxel; DVT, deep-vein thrombosis; EOC, epithelial ovarian carcinoma; FTC, fallopian tube cancer; gem, gemcitabine; GIP, gastrointestinal perforation; HR, hazard ratio; nab-pac, nab-paclitaxel; NR, not reported; OC, ovarian cancer; OS, overall survival; pac, paclitaxel; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PPC, primary peritoneal cancer; PR, partial response; RR, response rate; SD, stable disease; topo, topotecan; TIA, transient ischemic attack; TTP, time to progression; UPC, uterine papillary serous carcinoma.

^a Trial was closed early due to rate of GIP (11.4%). A total of 3 treatment-related deaths occurred.

^b Represents interim data.

^c OS data are immature, with only 48.6% of patients having had an event.

^d Selected AEs described.

Table 3
Efficacy and Safety in Phase II/III Trials of PARP Inhibitors

Trial	Setting	Treatment	RR, %	SD, %	Outcomes	Reported grade 3 to 4 AEs
Olaparib						
Audeh [93]; phase II (N = 57)	Recurrent EOC/PPC/FTC with confirmed <i>BRCA1</i> or <i>BRCA2</i> mutations	Olaparib 400 or 100 mg BID	33 (400 mg); 13 (100 mg)	36 (400 mg); 29 (100 mg)	PFS, 5.8 mo. (400 mg); 1.9 mo. (100 mg)	Nausea, fatigue, anemia, vomiting, neutropenia, GERD, lymphopenia
Gelmon [94]; phase II (N = 90)	Advanced high-grade serous and/or undifferentiated and/or known <i>BRCA</i> -mutated OC/PPC/FTC (n = 64) or triple-negative BC (n = 26)	Olaparib 400 mg BID	29 (OC only)	38 (OC only) ^a	PFS, 219 d (OC only)	Nausea, fatigue, decreased appetite, diarrhea, abdominal pain (OC only)
Ang [95]; phase II (N = 26) ^b	Advanced <i>BRCA1/2</i> -deficient OC	Olaparib followed by CT at progression	54 (olaparib only, before CT)	NR	NR	NR
Kaye [97]; phase II (N = 97)	Recurrent OC within 12 mo. of platinum therapy and confirmed <i>BRCA1</i> or <i>BRCA2</i> mutations	Olaparib 200 mg BID vs. olaparib 400 mg BID vs. PLD	25 vs. 31 vs. 18 (P = NS)	47 vs. 59 vs. 52 ^a	PFS, 6.5 vs. 8.8 vs. 7.1 mo. (HR for combined doses = 0.88; 80% CI, 0.51-1.56; P = 0.66) OS, HR (200 mg vs. PLD) = 0.66 (95% CI, 0.27-1.55); HR (400 mg vs. PLD) = 1.01 (95% CI, 0.44-2.27)	Nausea, fatigue, abdominal pain, vomiting, constipation (olaparib only), diarrhea (PLD only), asthenia, urinary tract infection (PLD only), anemia (olaparib only), rash/PPE (PLD only), stomatitis (PLD only)
Ledermann [98]; phase II (N = 265)	Platinum-sensitive, relapsed, high-grade serous OC/PPC/FTC; 2 prior platinum-based regimens and PR/CR to most recent regimen	Maintenance olaparib 400 mg BID vs. placebo	12 vs. 4	NR	PFS, 8.4 vs. 4.8 mo. (HR = 0.35; 95% CI, 0.25-0.49; P <0.001) OS, 29.7 vs. 29.9 mo. (HR = 0.94; 95% CI, 0.63-1.39; P = 0.75) ^b	Nausea, fatigue, vomiting, diarrhea, abdominal pain, anemia, asthenia, back pain
Iniparib						
Penson [99]; phase II (N = 41) ^b	Platinum-sensitive EOC/PPC/FTC	Iniparib + carbo/gem	70.6 ^c	NR	NR	NR
Birrer [100]; phase II (N = 48) ^b	Platinum-resistant EOC/PPC/FTC	Iniparib + carbo/gem	31.6 ^d	NR	PFS, 5.9 mo. ^d	NR

AE, adverse event; BC, breast cancer; BID, twice daily; BRCA, breast cancer susceptibility gene; carbo, carboplatin; CI, confidence interval; CR, complete response; CT, chemotherapy; EOC, epithelial ovarian carcinoma; FTC, fallopian tube cancer; gem, gemcitabine; GERD, gastroesophageal reflux disease; HR, hazard ratio; NR, not reported; NS, not significant; OC, ovarian cancer; OS, overall survival; PARP, poly-ADP-ribose polymerase; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PPC, primary peritoneal cancer; PPE, palmar-plantar erythrodysesthesia; PR, partial response; RR, response rate; SD, stable disease.

^a Stable disease for 8 weeks.

^b Represents interim data.

^c RR based on first 17 evaluable patients.

^d Efficacy reported for first 19 evaluable patients.